Cargando…
Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080507/ https://www.ncbi.nlm.nih.gov/pubmed/33932508 http://dx.doi.org/10.1016/j.annonc.2021.04.019 |
| _version_ | 1783685441319337984 |
|---|---|
| author | Barrière, J. Chamorey, E. Adjtoutah, Z. Castelnau, O. Mahamat, A. Marco, S. Petit, E. Leysalle, A. Raimondi, V. Carles, M. |
| author_facet | Barrière, J. Chamorey, E. Adjtoutah, Z. Castelnau, O. Mahamat, A. Marco, S. Petit, E. Leysalle, A. Raimondi, V. Carles, M. |
| author_sort | Barrière, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8080507 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-80805072021-04-29 Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors Barrière, J. Chamorey, E. Adjtoutah, Z. Castelnau, O. Mahamat, A. Marco, S. Petit, E. Leysalle, A. Raimondi, V. Carles, M. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2021-08 2021-04-28 /pmc/articles/PMC8080507/ /pubmed/33932508 http://dx.doi.org/10.1016/j.annonc.2021.04.019 Text en © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Barrière, J. Chamorey, E. Adjtoutah, Z. Castelnau, O. Mahamat, A. Marco, S. Petit, E. Leysalle, A. Raimondi, V. Carles, M. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title_full | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title_fullStr | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title_full_unstemmed | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title_short | Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors |
| title_sort | impaired immunogenicity of bnt162b2 anti-sars-cov-2 vaccine in patients treated for solid tumors |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8080507/ https://www.ncbi.nlm.nih.gov/pubmed/33932508 http://dx.doi.org/10.1016/j.annonc.2021.04.019 |
| work_keys_str_mv | AT barrierej impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT chamoreye impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT adjtoutahz impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT castelnauo impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT mahamata impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT marcos impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT petite impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT leysallea impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT raimondiv impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors AT carlesm impairedimmunogenicityofbnt162b2antisarscov2vaccineinpatientstreatedforsolidtumors |